Capital Raising for Healthcare Companies: Sources, Terms and What Investors Check
Healthcare companies raise capital from seven sources: bank and asset-based debt, PE buyouts, PE growth rounds, health system partners, angels and venture funds, family offices and physician investors. Three tests decide which fits. Can cash flow carry debt? Will you give up control? Do your likeliest investors also refer patients to you? Debt is the cheapest money if cash flow supports it. Minority equity from a growth fund, family office or physicians keeps control at the cost of dilution and governance rights. A buyout trades control for liquidity now. Every investor then checks the same core file: quality of earnings, payer mix, provider retention, licensure history and who owns the referral sources.
Updated November 20, 2026. Deal counts cover full-year 2025 (PESP) and Q1 through Q3 2026 (Kaufman Hall). Public multiples are Damodaran's January 2026 data. Spending figures are CMS data for 2024. Calculations labeled "our arithmetic" are ours, with assumptions stated.
Why investors keep coming. US physician and clinical services spending grew 8.1% to $1,109.7 billion in 2024, and CMS projects it will grow 5.5% a year on average from 2025 to 2034, per the CMS National Health Expenditure fact sheet. Total health spending reached $5.3 trillion in 2024, 18.0% of GDP. A growing spending base is the reason capital competes for practices, ASCs and services companies. It does not set your price. Your own cash flow and risk do.
Pick a Starting Source by Situation
| Your situation | Start with | Why | Main cost |
|---|---|---|---|
| Steady cash flow, you want no dilution | Bank, SBA or asset-based debt | Costs interest and covenants, not ownership | Fixed payments and limits on new debt and distributions |
| Need exceeds what debt can carry, you keep control | Debt plus a family office or PE minority check | Splits the need so less equity is sold | Protective provisions and reporting duties |
| Ready to take money off the table | PE control buyout with rollover | Liquidity now plus a second payout on the rolled equity | Loss of majority control |
| Specialty with active platform buyers | A platform offer and a minority offer side by side | The platform's price sets your minority investor's benchmark | Time spent on two processes |
| Likely investors refer patients to you | Settle the structure first, then pick a source | Referral rules can limit whole investor groups | Structuring work before any pitch |
| Pre-revenue health tech or device | Angels, venture funds, family offices | Equity priced on milestones, not EBITDA | Preferred terms and later-round dilution |
| Clinical or network fit with a system | Health system partner | Capital plus volume or contracts | Referral scrutiny and exposure to the system's own M&A |
Where Healthcare Private Equity Went in 2025: 1,029 Deals, 214 Growth Rounds
The Private Equity Stakeholder Project's 2025 review, built on PitchBook and LevinPro HC data, tracked 1,029 PE-backed healthcare deals in calendar 2025, involving 420 platform companies and 708 investment firms. PESP's methodology note says the final count is likely an underestimate. Shares are our arithmetic on PESP's counts.
| Deal type, 2025 (PESP) | Count | Share of 1,029 (our arithmetic) | What it means for a company raising capital |
|---|---|---|---|
| Add-on acquisitions | 664 | 64.5% | A platform buys your company. That is a sale, not a raise. |
| Growth investments | 214 | 20.8% | Minority capital. Owners keep the majority and negotiate governance rights. |
| Leveraged buyouts | 151 | 14.7% | A control sale. Owners give up the majority and negotiate any rollover. |
| All PESP-tracked deals | 1,029 | 100% |
PESP counts 1,029 deals in total and says the count is likely an underestimate.
Chart data
| Add-on acquisitions | 664 |
|---|---|
| Growth investments | 214 |
| Leveraged buyouts | 151 |
Source: Private Equity Stakeholder Project, PE healthcare deals 2025 in review
| Subsector, 2025 (PESP) | PE deals | What the count signals |
|---|---|---|
| Health IT | 151 | The busiest subsector by count |
| Dental care | 149 | 95% were add-ons by PE-owned platforms. Ten of the 18 platforms with the most 2025 deals were dental. |
| Outpatient care | 148 | 119 were add-ons. Platforms are consolidating specialty practices. |
| Medtech | 117 | Product companies, often with a regulatory approval path in the diligence file |
| Behavioral health | 56 | Fifth by count, well behind the top four |
What the counts show. In PESP's 2025 data, minority growth rounds (214) outnumbered leveraged buyouts (151). Dental is the clearest consolidation market. With 95% of 149 dental deals being add-ons, a dental group raising growth money is competing against a platform's purchase offer.
What they do not show. Dollars or check sizes. PESP publishes neither, so more growth deals than buyouts means minority capital is common, not that it is the larger pool. With 708 firms active, one conversation with one firm tells you little about market terms.
Get dollar figures from the investors themselves:
- How large is the fund this check comes from, how much is uncommitted and how much time is left in the investment period? The answers tell you how fast the firm can move and whether it can fund a follow-on.
- What were your last three healthcare checks, in dollars, and were they minority or control? This is the most reliable check-size data you will get, and it shows whether the firm actually does minority rounds.
- Do you own a platform in my specialty? If so, a growth round can be the first step toward an add-on. The private equity roll-up guide explains how roll-ups are built and what sellers give up.
- Which rights come with a minority stake? Expect requests for board seats and vetoes over new debt, budgets and a future sale. Each is negotiable.
Verify the answers. Private issuers file Form D notices with the SEC, and EDGAR full-text search lets you see which healthcare companies in your specialty have raised private capital and roughly when.
Valuation Benchmarks: Public Healthcare EV/EBITDA Multiples, January 2026
Investors price private healthcare companies against public comparables, then discount for size, concentration and illiquidity. The figures below are enterprise value to EBITDA for US public companies from Aswath Damodaran's NYU Stern dataset, data as of January 2026. They describe public company groups, not private deal prices.
| Sector (Damodaran classification) | Public companies in sample | EV/EBITDA, January 2026 | Private companies investors compare here |
|---|---|---|---|
| Healthcare Information and Technology | 115 | 21.27x | Health IT, revenue cycle software, digital health |
| Healthcare Products | 204 | 19.78x | Devices and medtech |
| Total US market, excluding financials | 4,822 | 16.95x | Reference point |
| Drugs (Biotechnology) | 496 | 15.78x | Biotech, often valued on pipeline rather than EBITDA |
| Drugs (Pharmaceutical) | 228 | 15.25x | Specialty pharma |
| Healthcare Support Services | 104 | 11.17x | MSOs, staffing, billing and other services |
| Hospitals/Healthcare Facilities | 31 | 8.86x | Hospitals, ASCs, imaging and other facility operators |
Facilities sit at the bottom, well below the 16.95x market reference. Health IT and devices sit above it. A physician practice or single ASC prices below its public sector multiple because one site, a few surgeons and a concentrated payer mix carry more risk than a diversified public operator. Damodaran's data does not measure that private discount, and it varies by deal. The sector ranking describes public groups and does not predict the multiple on any single private deal. Ask each investor which private comparables it used and what they sold for.
Compare like with like. These are enterprise value multiples. To set an offer against them, convert the investor's equity value to enterprise value: add debt, subtract excess cash, and ask how any preferred equity or minority interest in a joint venture is treated, since the answer depends on whether your EBITDA includes that entity in full. A $20,000,000 equity value with $2,000,000 of debt, no cash and no preferred is a $22,000,000 enterprise value. Test your own numbers in the practice valuation calculator.
Seven Healthcare Capital Sources Compared
| Capital source | Best-fit stage | What you give up | How the check gets sized | What they diligence first | Regulatory area in play |
|---|---|---|---|---|---|
| Bank, SBA or asset-based debt | Cash-flowing practices, ASCs, imaging centers | No ownership. Covenants limit new debt and distributions. | Advance against eligible collateral, capped by cash flow available for debt service | Receivables aging, payer mix, equipment value, cash flow | Lender security over Medicare and Medicaid receivables |
| PE control buyout | Mature, profitable groups ready to sell | Majority ownership | EBITDA times a negotiated multiple, less debt | Quality of earnings, provider retention, payer contracts | Rollover equity and pay to physicians who stay |
| PE growth minority | Proven model that needs expansion capital | Minority stake, board seats and protective provisions | The fund's target ownership and fund size | Growth plan, management depth, unit economics | Securities offering rules, referral ties of physician owners |
| Strategic or health system partner | Companies with clinical or network fit | Anything from a contract to a full merger | Value of the service line or network to the partner | Clinical fit, network fit, culture | Referral rules, state transaction notice, tax-exempt partner rules |
| Angel and venture groups | Health tech, devices, early-stage services | Minority stake, preferred terms, board seats in later rounds | Cash needed to reach the next milestone | Team, market size, clinical and regulatory path | Securities offering rules, FDA path for devices |
| Family office direct | Seed through mature, depending on the family | Minority stake plus the information rights and protective provisions the family sets | The family's per-deal allocation and follow-on reserve | Founder's own money in the deal, alignment, downside protection | Securities offering rules, referral ties of family members |
| Physician investors | Physician-led ASCs, practices, platforms | Minority stake spread across many small holders | Many small checks above a minimum you set | Deal mechanics, who else is in, the founder's clinical standing | Referral rules for investors who refer patients, for your healthcare attorney to review |
Debt first, if it fits. The SBA 7(a) program is the SBA's main small business loan program. The program sets a loan limit that can change, so confirm the current rule with the lender or your attorney. Eligibility, permitted uses and loan size depend on the borrower, the transaction and the lender's underwriting, so confirm whether a specific acquisition or expansion qualifies. Conventional bank and asset-based lenders size against receivables, equipment and cash flow.
Sort your options in this order:
- Cash flow test. If steady cash flow covers loan payments after taxes and capital spending, price debt before equity. Size it with the debt capacity calculator.
- Referral test. If your likeliest investors refer patients to you, settle the structure before you pitch. It decides who can invest and how returns are paid.
- Control test. If you will not give up control, drop buyouts and add-ons. Those made up 815 of PESP's 1,029 tracked deals in 2025, or 79.2% (our arithmetic). Your realistic universe is the minority PE slice plus family offices, angels and physicians.
Land the anchor first. Secure a health system, a strategic in your specialty, a known operator or a recognized family office before working the wider list. Ask up front whether you may name the anchor to later investors. Decide before the first meeting what you will offer an anchor, such as a preferred return or a senior position. If the anchor refers patients, every concession has to clear the referral test.
Term Sheet Checklist: Seven Terms That Matter More Than Valuation
| Term | What it does | What to negotiate |
|---|---|---|
| Pre-money valuation | Sets the price per share and your dilution | The enterprise value and EBITDA multiple it implies, checked against the benchmark table |
| Liquidation preference | Decides who gets paid first, and how much, in a sale | 1x without participation. See the worked example below. |
| Board seats | Gives the investor a vote on strategy | Seat count relative to founders, plus an independent seat |
| Protective provisions | Investor vetoes over specific actions | Limit the list to new debt above a threshold, new senior securities and a sale. Keep clinical decisions with physicians. |
| Drag-along and tag-along | Forces or allows minority holders to join a sale | The price floor and vote threshold that trigger a drag |
| Anti-dilution | Protects the investor if a later round prices lower | Weighted average rather than full ratchet |
| Follow-on and tranche pricing | Sets the price of later checks | Fix the per-share price for every tranche at signing |
Example: what a liquidation preference costs in a sale. Hypothetical figures, our arithmetic. Assumptions: an investor puts in $5,000,000 for 20% of the company, there is one class of preferred, no option pool and no other preferences. Proceeds are equity value to all holders, after debt and transaction fees and before taxes. A non-participating preference pays the investor the greater of $5,000,000 or 20% of proceeds. A participating preference pays $5,000,000 first, then 20% of what remains. "Other holders" means founders and everyone else in the remaining 80%.
| Equity proceeds | Non-participating: investor | Other holders | Participating: investor | Other holders |
|---|---|---|---|---|
| $15,000,000 | $5,000,000 (preference beats 20%, which is $3,000,000) | $10,000,000 | $5,000,000 + 20% × $10,000,000 = $7,000,000 | $8,000,000 |
| $30,000,000 | $6,000,000 (20% beats the $5,000,000 preference) | $24,000,000 | $5,000,000 + 20% × $25,000,000 = $10,000,000 | $20,000,000 |
At $30,000,000, participation moves $4,000,000 to the investor on the same 20% stake. Run every term sheet at a low, middle and high exit price before you compare headline valuations.
Dermatology's 24 Deals and Eye Care's 22: The 2025 Outpatient Signal
Becker's ASC Review, reporting PESP's 2025 outpatient data, counted 148 deals involving outpatient care providers in 2025, including 119 add-on acquisitions. Among the subsectors it listed by deal count, dermatology had 24, eye care 22 and oncology 9.
These come from the same PESP 2025 dataset as the totals above, so they compare directly. By our arithmetic, add-ons were 80.4% of outpatient deals (119 of 148), against 64.5% across all 1,029 PESP-tracked healthcare deals. Dermatology and eye care together were 46 deals, or 31.1% of the outpatient total. The counts are small, so a handful of deals could reorder the ranking.
Platforms are the main buyers of outpatient practices. A dermatology or eye care group raising growth money is usually competing with a buyout offer from a platform already in its market. A minority investor has to offer something the platform does not, and that is usually continued control. Oncology owners have fewer comparable deals to point to, which makes a valuation harder to defend.
Before you take outpatient growth money, ask:
- Which platforms in my specialty and region bought practices in the last year? Their offers set the price your minority investor is competing against.
- Does the investor already own a platform in my specialty? If so, your data room is a competitor's research file. Stage disclosure until terms are signed.
- What happens to my equity if the investor later sells to a platform? Check drag-along and tag-along terms and how a sale is triggered.
- Is the valuation based on comparable deals or my own projections? In a thin specialty like oncology, ask which comparables the investor used.
Health Systems in 2026: Sellers of Assets, Partners With Strings
For physician groups and ASC owners, health systems matter in two ways. They sell assets you can buy, and they invest capital that can come with referral expectations. Both trace back to thin margins.
The press release for Kaufman Hall's Q3 2026 M&A report, dated October 13, 2026, put the year-to-date hospital operating margin at 2.5% including allocations, with nearly 43% of hospitals operating at a loss, on data through August 2026. Non-labor expenses rose 6% year-to-date per adjusted discharge compared with 2025, with supply costs up 5% and drug costs up 6%.
| Period | Hospital and health system transactions announced (Kaufman Hall) |
|---|---|
| Q1 2026 | 22 |
| Q2 2026 | 18 |
| Q3 2026 | 16 |
| 2026 through Q3 (partial year) | 56 |
| All of 2025 (full year) | 46 |
Source: Becker's Hospital Review reporting Kaufman Hall data, with the Q3 2026 count matching Kaufman Hall's October 13, 2026 release.
Pace versus trend. By our arithmetic, 2026 through Q3 averages about 18.7 deals per quarter (56 ÷ 3), against 11.5 per quarter in full-year 2025 (46 ÷ 4). Inside 2026 the count fell each quarter, from 22 to 18 to 16. A strong first quarter carries the year-to-date total.
Who bought and sold. Divestitures were nearly one-third of the 16 transactions announced in Q3 2026, about 5 by our arithmetic. Not-for-profit organizations were most of the acquirers. Kaufman Hall reported $8.2 billion in Q3 2026 transacted revenue and an average seller size approaching $586 million in annual revenue. Those figures measure the size of the organizations, not prices paid. Kaufman Hall counted 2 mega mergers in Q3 2026, the third straight quarter with such deals, and said 2026 could set a record for transactions in which the smaller party has more than $1 billion in annual revenue.
A not-for-profit system has no shareholders to sell stock to. Beyond borrowing and philanthropy, selling a non-core hospital, service line or outpatient stake is one of its few ways to raise cash. That is the opening for physician groups.
Buying a divested asset. If the facility's Medicare provider agreement is assigned to you, it comes with its original terms, including any open plan of correction. Before you price the asset, pull:
- The last several survey reports and any open plan of correction
- Every payer contract and whether each one can move to a new owner
- Staffing levels, open positions and contract labor spend for the past year, benchmarked against local wage data from the BLS Health Care and Social Assistance page
- Deferred maintenance and equipment replacement needs
Price the open findings and the cost of fixing them into your offer.
Before you take health system money, ask:
- Could any payment, price term or return be read as rewarding referrals between us?
- Does any state require advance notice of this deal? See the healthcare M&A process guide.
- What happens to our joint venture if the system is acquired? With mega mergers in three straight quarters, your partner's owner can change mid-deal.
Pitching Physician Investors: Check Size, Mechanics and Who Can Invest
Set the minimum for the investor you most need. A high clinical salary does not mean a physician has much liquid capital or can decide quickly. If the round depends on surgeons who draw a salary rather than practice distributions, set the minimum for them and expect questions on liquidity and lockup length.
Model the cap table before you set the minimum. The minimum check sets how many holders you manage for years.
Example: hypothetical figures, our arithmetic. A $5,000,000 physician round at a $20,000,000 pre-money equity value gives investors 20% of a $25,000,000 post-money company.
| Minimum check | Maximum investors if all invest the minimum | Ownership per minimum check |
|---|---|---|
| $50,000 | 100 | 0.2% |
| $100,000 | 50 | 0.4% |
| $250,000 | 20 | 1.0% |
Each holder adds a K-1, consent signatures and investor calls. Fifty holders at 0.4% each is a different company to run than twenty at 1.0%. A lower minimum widens the pool but multiplies the administration and can change which offering route fits.
Explain the mechanics. Physicians who invest want the inner workings: how cash flows, who gets paid first and what happens if a partner leaves or retires. A pitch without those answers reads as evasive. If the company is physician-led, say so in the first sentence.
Decide who may invest before you pitch. Investors who refer patients to the company, physicians or not, raise federal and state legal questions that your healthcare attorney should review before you accept their money. The answers can depend on the service, the ownership structure and how distributions are calculated. Pitching first and screening later means telling a referring colleague no after you asked for money. The physician investor guide covers pitch structure and investor relations.
Write the outreach plan before the first contact. How you find investors affects which offering route fits. A raise built on emails to a hospital staff list and one built on private conversations can fall under different routes.
| Outreach channel | Who it reaches | Business tradeoff | Offering question it raises |
|---|---|---|---|
| Private conversations with physicians you know | A small, warm pool | Slow, but each investor already trusts the founder | Which route fits and how you confirm each investor's status |
| Email to a hospital or practice staff list | A wide pool, many with referral ties | Fast reach, but more screening and more small holders | Whether broad outreach fits the route, plus referral screening |
| Introductions from a paid finder | People the finder knows | Wider reach, at the cost of a fee | Whether and how you may pay the finder. Look the finder up on FINRA BrokerCheck first. |
| Investor events or online posts | Strangers, including non-physicians | Largest reach, least control over who responds | Whether public outreach fits the route |
Family Offices and Healthcare Founders: Screening and the First Call
Confirm status early. Family offices invest directly or through an LLC, partnership or trust. Ask how the investing entity qualifies for your offering and collect the supporting documents at the term sheet stage, not the week of closing.
Use the first call to qualify. Ask each family five questions:
- Does healthcare sit inside your stated mandate, and which subsectors?
- What is your typical check size in dollars, and do you reserve capital for follow-ons?
- Do you lead, co-invest alongside a sponsor or only follow?
- Does anyone in the family or its investment team refer patients in our market?
- What reporting and governance rights do you expect after closing?
A mismatch on questions 1 through 3 ends the conversation before you spend a site visit on it. A yes to question 4 means the structure has to be settled before terms. If the answers fit, a visit to the clinic or surgery center becomes the second meeting.
Size the round to clear. Set a target your anchor and the families' stated check sizes can fill, and treat a full close as proof for the next raise. Test the number in the capital raise sizing calculator.
Narrow the pitch. A specific description such as "orthopedic ASCs in one region" is easier for a family office to test against its mandate than "healthcare services." Match the description to the family's stated mandate.
Plan for a slow close. At many family offices, decisions run through a small team, sometimes a single principal, so timing varies widely. Build cash runway around a slow close, and close in tranches if the family wants to see reporting first. The healthcare data room checklist covers the materials.
Nine-Item Data Room Checklist for a Healthcare Raise
Start from a core structure, then tailor it to the specialty, the offering and the stage. A seed-stage device company and a mature dermatology group should not upload the same folders. The healthcare data room checklist gives a full folder structure.
| Data room item | What healthcare investors look for | Red flag and what it changes |
|---|---|---|
| Audited financials | Revenue and margin trends that match tax returns and bank statements | Gaps between audited revenue and bank deposits point to billing or recognition problems |
| Payer mix and receivables aging | Single-payer dependence, government versus commercial exposure, collection speed | Old receivables carried at full value overstate what a lender will advance |
| Licensure, accreditation and survey history | Current facility, provider and state licenses, plus any plan of correction | An open finding can delay a closing and carries forward to a buyer |
| Ownership of referral sources | Which owners or investors refer patients, and the compliance analysis for each | Missing analysis means the investor inherits the risk |
| Practice ownership and MSO structure | How the management company and professional entity split ownership and fees | Fee terms tied to professional revenue get close review |
| Provider agreements | Employment terms, non-competes where enforceable, how pay ties to productivity | Short terms with key surgeons mean the revenue can walk out |
| Cap table and prior raises | Every holder, how each earlier raise was documented, any side letters | A defective earlier raise creates exposure that new money has to cover |
| Due diligence questionnaire | Written answers on payer concentration, referral-source ownership, practice ownership and litigation | Answering before the first meeting shortens diligence and shows your gaps |
| One-pager and verbal pitch | The deal on one page and in two minutes of speaking | If you cannot explain it briefly, physician investors assume it is too complex |
Put payer mix in national context. Per the CMS National Health Expenditure fact sheet, 2024 spending was 31% private health insurance ($1,644.6 billion), 21% Medicare ($1,118.0 billion) and 11% out of pocket ($556.6 billion). CMS projects Medicare to grow fastest of the major payers, at 7.7% a year on average from 2025 to 2034. A practice heavily weighted to Medicare is tied to the fastest-growing payer and to its fee schedule.
Paperwork is not proof. A complete data room can still be wrong. Niche specialists catch what general checks miss: a revenue cycle expert reviewing a billing company, or a former ASC administrator reviewing a surgery center. Serious investors bring specialists like these. Prepare for their questions.
Worked Example: How an ASC Could Split a $5,000,000 Raise
Example: a hypothetical company with illustrative figures. All calculations are our arithmetic. Ownership figures ignore fees, option pools and liquidation preferences.
A physician-owned ambulatory surgery center needs $5,000,000 to add 2 operating rooms. Assumptions: $2,500,000 of normalized EBITDA, no funded debt, no excess cash and normal working capital before the raise. On that debt-free, cash-free basis, the owners' $20,000,000 pre-money equity value equals enterprise value, or 8.0x EBITDA. If the center instead carried $2,000,000 of debt, the same 8.0x enterprise value would leave $18,000,000 of equity value. This is a simplified comparison. In a real transaction, working capital adjustments, fees and other claims change what owners receive.
The public Hospitals/Healthcare Facilities group traded at 8.86x EV/EBITDA across 31 companies in Damodaran's January 2026 data. A single-site private ASC carries more risk than that group, so 8.0x is an aggressive ask. Expect investors to push it lower. Two formulas drive every route:
- Post-money equity value = pre-money equity value + new equity capital
- Investor ownership = new equity capital ÷ post-money equity value
Debt stays out of the equity math, which is why mixing debt and equity changes dilution.
Route A: bank debt plus family office equity. A $3,000,000 loan secured by equipment and receivables covers most of the need. A family office invests $2,000,000. Post-money equity is $20,000,000 + $2,000,000 = $22,000,000. The family office owns $2,000,000 ÷ $22,000,000 = 9.1%. The founders keep 90.9% and majority control, subject to lender covenants and whatever protective provisions the family negotiates.
Loan screen. Assume an 8% fixed rate and 7-year monthly amortization, both hypothetical. The payment is about $46,800 a month, or about $561,000 a year. EBITDA of $2,500,000 is about 4.5x that payment. This is an EBITDA-to-payment ratio, a rough screen, not a lender's debt service coverage ratio. Lenders measure cash available after taxes, capital spending and distributions, under their own definition. If maintenance capital spending runs $400,000 a year (hypothetical), cash before debt service falls to $2,100,000 and the ratio to about 3.7x, before taxes. Ask each lender for its definition in writing. Debt is $3,000,000 ÷ $2,500,000 = 1.2x EBITDA. The loan sits ahead of equity: in a later sale, the outstanding balance comes out of proceeds before owners are paid.
Tranche math. The equity can close in two tranches: $500,000 at signing and $1,500,000 after a quarter of reporting. Assume the $20,000,000 pre-money equals 20,000,000 units at $1.00 each.
| Step | Units issued | Total units after | Family office units held | Family office ownership at that point |
|---|---|---|---|---|
| Before raise | 20,000,000 | 0 | 0% | |
| Tranche 1: $500,000 at $1.00 | 500,000 | 20,500,000 | 500,000 | 2.4% (500,000 ÷ 20,500,000) |
| Tranche 2: $1,500,000 at $1.00 | 1,500,000 | 22,000,000 | 2,000,000 | 9.1% (2,000,000 ÷ 22,000,000) |
The tranche 1 stake dilutes from 2.4% to 2.3% when tranche 2 closes. In the final 9.1%, tranche 1 units are 2.3% and tranche 2 units are 6.8% of 22,000,000 units. The 9.1% holds only if tranche 2 is priced at the same $1.00 per unit, which values the company at $20,500,000 pre-money for the second close. If tranche 2 priced at $1.10 instead, $1,500,000 would buy about 1,363,636 units, and the family office would own about 1,863,636 ÷ 21,863,636 = 8.5%. Fix the per-unit price for both tranches in the term sheet.
Route B: PE growth minority. A private equity fund invests $5,000,000. Post-money equity is $25,000,000. The fund owns $5,000,000 ÷ $25,000,000 = 20%. Expect requests for board seats and protective provisions over budgets, new debt and any future sale, and run the preference math from the term sheet section.
Route C: local physician investors. Area surgeons invest $5,000,000 at the same valuation, also 20%. If those surgeons refer cases to the center, their investment raises legal questions your healthcare attorney should review before you accept their money. The answers can limit who may invest and how returns are paid, and some referring surgeons may be ruled out, which shrinks the pool.
| Route | Ownership given up | Control rights | Repayment obligation | Regulatory areas in play |
|---|---|---|---|---|
| A: debt plus family office | 9.1% | Founders hold the majority. Lender covenants and negotiated protective provisions apply. | $3,000,000 principal plus interest, about $561,000 a year at the assumed terms | Securities offering rules for the equity, receivables collateral |
| B: PE growth minority | 20% | Board seats and protective provisions, as negotiated | None, but the investor expects an exit | Securities offering rules, referral ties of physician owners |
| C: physician investors | 20% | Many small holders, consent rights if loosely drafted | None | Referral rules for investors who refer patients, securities offering rules |
How to choose: Route A gives up the least ownership but adds the most fixed cost. Route B brings governance and an exit clock. Route C ties investors to the center's volume, which helps retention but carries the heaviest compliance load.
If the raise turns into a sale offer, the deal proceeds calculator estimates what owners take home.
Compliance Areas That Shape a Healthcare Raise
Healthcare raises carry more legal gates than raises in most industries, and several decide who may invest, not only how. State review is widening. Latham & Watkins' 2026 review of state healthcare transaction laws documents states extending notice and review to deals involving significant equity investors and management services organizations, not only outright sales. Build that review into the timeline before you set a closing date.
Bring a complete file to your first attorney meeting. A prepared founder gets clearer answers and pays for less fact-finding.
| What to bring | Effect on the raise | Where it comes from on this page |
|---|---|---|
| Draft investor list, with every referral relationship flagged | Referral ties shape who may invest and how returns are paid | Referral test, family office question 4 |
| Written outreach plan | How you find investors affects which offering route fits | Outreach channel table |
| Cap table and documents from every earlier raise | Gaps in earlier raises become the new investor's problem | Data room checklist |
| Draft term sheet with the preference, tranche and minimum check terms | The economics and the offering get reviewed together | Term sheet checklist, tranche math |
| Ownership chart for the practice, any MSO and any joint venture | Structure drives which rules apply to investors | Data room checklist |
| Any finder or placement agent arrangement, with a BrokerCheck printout | Paying for introductions raises separate questions | Outreach channel table |
| Target close date and cash runway | Shows which steps could move the date | Family office slow-close planning |
High-risk area: Securities rules for a healthcare raise
Private raises run under SEC and state securities rules, and healthcare adds federal referral and self-referral rules and state ownership rules on top. The right answers depend on your state, your structure and your investor list. Engage a securities attorney, with a healthcare attorney for the referral and ownership questions, and bring these questions.
Questions to ask your attorney
1. Which securities offering route fits our investor list and outreach plan?
- Why ask: The route controls who may invest, whether non-accredited investors may take part, how you may find investors and what you must give them.
- What can go wrong: Outreach that does not match the route can put the whole offering in question after money is in.
2. How should we confirm and document each investor's status, including family offices investing through an LLC, partnership or trust?
- Why ask: Entity investors qualify in different ways, and the paperwork is easier to collect at the term sheet stage than at closing.
- What can go wrong: Weak documentation can delay a close or leave questions open for later investors and buyers.
3. What disclosure should physician investors receive, and how should it describe referral relationships and risks?
- Why ask: Physician investors often know the founder personally, which makes an informal pitch feel normal.
- What can go wrong: A thin or optimistic disclosure invites investor disputes if results fall short.
4. May we pay anyone who introduces investors to us, and on what terms?
- Why ask: Finder fees are common in physician and family office networks, and broker-dealer registration rules govern who may be paid for raising capital.
- What can go wrong: A commission paid to an unregistered finder can create problems for the finder and for your offering.
5. How do federal referral and self-referral rules interact with the offering for investors who refer patients to us?
- Why ask: Securities rules and referral rules apply to the same investor at the same time. Whether a structure fits those rules is fact-specific, so ask your healthcare attorney.
- What can go wrong: A structure that works for the offering can still limit who may invest or how returns are paid, which shrinks the pool late in the process.
6. If owners roll equity into a platform or accept an earnout, what information rights and protections should we ask for?
- Why ask: Rollover equity and earnouts tie part of the sale price to a business the sellers no longer control.
- What can go wrong: If the platform struggles, the rolled equity or earnout can be worth far less than expected.
7. Could this minority investment or MSO structure trigger state healthcare transaction notice or review alongside the securities steps?
- Why ask: Latham & Watkins' 2026 review shows states extending review to equity investments and management arrangements, not only outright sales.
- What can go wrong: A review step found late moves the closing date and the cash runway with it.
8. Were our earlier raises documented in a way new investors and their counsel will accept?
- Why ask: New investors review every prior raise in diligence.
- What can go wrong: Gaps in earlier raises slow diligence, change terms or require cleanup before new money closes.
Other topics to raise with your attorney
- Corporate practice of medicine limits and whether investors buy into the practice or an MSO
- Tax treatment of the raise for owners, and any rules a tax-exempt partner brings
- Whether a larger deal needs federal antitrust premerger review
- Medicare change of ownership effects when buying a divested facility
- State securities filings that apply to the offering
Related reading: the healthcare compliance due diligence guide and the deal structures guide.
Questions practice owners and investors ask
How much private equity money goes into healthcare growth rounds instead of buyouts?
PESP's 2025 review counts deals, not dollars. Of 1,029 PE-backed healthcare deals it tracked in calendar 2025, 214 were growth investments and 151 were leveraged buyouts, so growth rounds led by count. The counts say nothing about the capital behind each deal, and PESP's methodology note says the total is likely an underestimate. For dollar capacity, ask each investor for its fund size, its uncommitted capital and the dollar size of its last three healthcare checks.
Why are so many hospitals selling assets or merging instead of raising capital in 2026?
Margins are thin. Kaufman Hall's October 13, 2026 release for its Q3 2026 M&A report put the year-to-date hospital operating margin at 2.5% including allocations, with nearly 43% of hospitals operating at a loss, on data through August 2026. Not-for-profit systems, most of the Q3 2026 acquirers, have no shareholders to sell stock to, so borrowing, philanthropy and asset sales are their main sources of cash. Divestitures made up nearly one-third of the 16 deals announced in Q3 2026, which puts hospital assets in front of physician-group buyers.
Which outpatient specialties attracted the most investor deals in 2025?
Becker's ASC Review, reporting PESP's 2025 data on 148 outpatient care deals, listed dermatology with 24 deals, eye care with 22 and oncology with 9. Add-ons made up 119 of the 148, so most activity was platforms buying practices, not funding them. An owner in these specialties raising growth capital should expect investors to benchmark the plan against a platform buyout offer.
What does a liquidation preference cost founders in a sale?
It depends on the sale price and whether the preference participates. In this page's hypothetical, a $5,000,000 investment for 20% with a 1x non-participating preference takes $6,000,000 of $30,000,000 in equity proceeds and leaves other holders $24,000,000. With a participating preference the investor takes $10,000,000 and other holders keep $20,000,000. Run the math at a low, middle and high exit price before you sign.
Can non-accredited physicians invest in a healthcare company's private offering?
Some securities offering routes allow it and others do not. Ask a securities attorney which route fits before the first pitch.
Sources
- Private Equity Stakeholder Project, "Private Equity Healthcare Deals: 2025 in Review", full-year 2025 deal counts, PitchBook and LevinPro HC data
- Becker's ASC Review, "The outpatient specialties that dominated 2025 deal activity", reporting PESP 2025 outpatient data
- Kaufman Hall, Q3 2026 M&A Quarterly Activity Report press release, October 13, 2026, margin and expense data through August 2026
- Becker's Hospital Review, coverage of Kaufman Hall Q3 2026 hospital transaction data, Q1 through Q3 2026 and full-year 2025 counts
- Aswath Damodaran, NYU Stern, EV/EBITDA multiples by sector (US), data as of January 2026
- Centers for Medicare & Medicaid Services, National Health Expenditure fact sheet, 2024 spending and 2025 to 2034 projections
- U.S. Small Business Administration, 7(a) loans, program overview
- U.S. Securities and Exchange Commission, EDGAR full-text search, Form D notices and other filings
- FINRA BrokerCheck, registration and disclosure history for firms and individuals
- U.S. Bureau of Labor Statistics, Health Care and Social Assistance industry page, employment and wage data
- Latham & Watkins, "US State Regulatory Spotlight on Healthcare Transactions: Reflections From 2026"